You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Respiratory
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Login
Username:

Password:


Related Headlines

Merck completes acquisition of Cidara Therapeutics for USD9.2bn

Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial

Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China

INOVIO's INO-3107 Biologics License Application accepted by US FDA

Italfarmaco and JCR PHarmaceuticals strike Japan deal for givinostat and expand rare disease collaboration

Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11

Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA

Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance

GSK agrees US pricing framework to expand access to respiratory medicines

Century Health partnerss with Tessel Biosciences to advance early drug development in COPD

Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema

Hikma launches TYZAVAN in US

PureTech clears key FDA milestone for Phase 3 development of deupirfenidone

DELFI Diagnostics presents preliminary data showing potential for blood-based lung cancer detection in non-smoking population

Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026